論文

査読有り
2018年4月1日

Combined effects of neoadjuvant letrozole and zoledronic acid on γδT cells in postmenopausal women with early-stage breast cancer

Breast
ダウンロード
回数 : 49
  • Tomoharu Sugie
  • ,
  • Eiji Suzuki
  • ,
  • Akira Yamauchi
  • ,
  • Kazuhiko Yamagami
  • ,
  • Norikazu Masuda
  • ,
  • Naomi Gondo
  • ,
  • Eriko Sumi
  • ,
  • Takafumi Ikeda
  • ,
  • Harue Tada
  • ,
  • Ryuji Uozumi
  • ,
  • Shotaro Kanao
  • ,
  • Yoshimasa Tanaka
  • ,
  • Yoko Hamazaki
  • ,
  • Nagahiro Minato
  • ,
  • Masakazu Toi

38
開始ページ
114
終了ページ
119
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.breast.2017.12.017
出版者・発行元
Churchill Livingstone

Introduction Adjuvant bisphosphonates lead to better prognosis in postmenopausal breast cancer. However, the association between clinical outcomes and immune modulation by them is still unclear. Methods In this prospective, open-label phase II study, postmenopausal women with estrogen receptor-positive and human epidermal growth factor receptor 2-negative early-stage breast cancer received neoadjuvant letrozole (LET) for one month, followed by treatment with a single dose of zoledronic acid. The patients underwent an additional 5 months of treatment with LET prior to surgery. The primary endpoint was the tumor objective response rate (ORR) determined by diameter via MRI. The association between the ORR and γδT cell frequencies was assessed as a secondary endpoint. Results Out of sixty patients, 55 patients were evaluable for response by MRI. The ORR for LET with zoledronic acid was 38.2% (21/55), which was comparable to that of historical controls (45%). A decrease in the frequency of the Vδ2 T cell subset was observed throughout treatment, and Vδ2 T cells were activated for 6 months. In planned subgroup analyses, patients with low frequencies of Vδ2 T cells prior to zoledronic acid infusion experienced a favorable tumor response compared to those with high frequencies (59.3% [16/27] vs 17.9% [5/28], p =.002). There were no serious adverse events with this treatment regimen. Conclusion These results showed that neoadjuvant LET with zoledronic acid could not achieve overall effect for local tumor response. However, patients with a low frequency of γδ T cells would benefit from the treatment including zoledronic acid. (UMIN 000008701).

リンク情報
DOI
https://doi.org/10.1016/j.breast.2017.12.017

エクスポート
BibTeX RIS